Allogeneic CD19-targeting CAR-T cell therapy with SPPL3 knockout (TCR Reserved and Power3)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic CD19-targeting CAR-T cell therapy with SPPL3 knockout (TCR Reserved and Power3), covering 2025-05-25 to 2025-05-25. Get the full timeline:
Most recent: Clinical Trial Update: TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma [Phase 1, Phase 2]